Stratification of patients with severe asthma

The Lancet Respiratory Medicine

Volumn 3, Issue 5, 2015, Pages 330-331

  Bousquet, Jean ^a,b,c  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b UMR S 1168   (France)

^c LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BENRALIZUMAB; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; FLUTICASONE; LONG ACTING DRUG; MEPOLIZUMAB; OMALIZUMAB; PLACEBO; RESLIZUMAB; MONOCLONAL ANTIBODY;

ASTHMA; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; EOSINOPHIL COUNT; EUROPE; HUMAN; MEDICAL DECISION MAKING; NOTE; PATIENT SELECTION; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFLAMMATION; UNITED STATES; EOSINOPHIL; FEMALE; IMMUNOLOGY; MALE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; EOSINOPHILS; FEMALE; HUMANS; MALE;

EID: 84929024812     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(15)00057-0     Document Type: Note

References (9)

1. Castro M, Zangrili J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 2015, published online Feb 23. http://dx.doi.org/10.1016/S2213-2600(15)00042-9.
2. Castro M, Wenzel SE, Bleecker ER, et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med 2014, 2:879-890.
3. Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014, 371:1198-1207.
4. Kips JC, O'Connor BJ, Langley SJ, et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody in severe persistent asthma: a pilot study. Am J Resp Crit Care Med 2003, 167:1655-1659.
5. Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007, 176:1062-1071.
6. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009, 360:973-984.
7. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009, 360:985-993.
8. Hanania NA, Wenzel S, Rosen K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 2013, 187:804-811.
9. Bousquet J, Rabe K, Humbert M, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med 2007, 101:1483-1492.